CompletedPhase IInterventional

Phase I Study: QSC301634

This is an early research study, known as a Phase I trial, called QSC301634. Its main purpose is to explore a new potential treatment. At this moment, the in-depth information about what specifically is being tested, the health conditions it aims to address, and the exact requirements for joining are not yet public. This is a common practice in early research. The full details explaining everything about the study will be made available to everyone within 30 months after the study has officially finished. The study is open to both men and women between the ages of 18 and 55.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Evecxia Therapeutics, Inc.

Enrolment target

Start

31 Mar 2026

Estimated completion

16 May 2026

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

You might be seeing information about a research study called QSC301634. This is what we call a 'Phase I' study. In simple terms, early-phase studies like this are often the first time a new treatment is tried in people. The main goals are usually to check if the new treatment is safe, what the right dose might be, and how it acts in the body. It's a really important step in developing new medicines.

Currently, many of the specific details about this study are not publicly available. This means we don't yet know exactly what treatment is being investigated, what health condition it's designed to help, or the full list of things that would make someone suitable (or unsuitable) to join. This isn't unusual for early-stage research; sometimes sponsors of the study keep these details private for a period.

However, it's important to know that transparency is a key part of medical research. All the missing details will be made public within 30 months after the study has fully ended. This ensures that everyone can eventually see the full picture of what was studied and what was found. For now, we know the study is looking for volunteers aged between 18 and 55, and it's open to both men and women.

Key takeaways

This is an early-stage (Phase I) research study.
The full details about the treatment and specific conditions are not yet public.
All study details will be released within 30 months of the study ending.
The study is for adults aged 18 to 55, open to both men and women.
Participation would involve being closely monitored by a research team.

Who may be eligible?

At the moment, the full details about who can and cannot join this study haven't been made public. This means we don't have a clear list of health conditions or other factors that researchers will be looking for.

However, we do know that the study is open to adults of all genders. You must be aged between 18 and 55 years old to be considered for this research.

Detailed information about specific health requirements or conditions that would prevent someone from taking part will be shared later, once the study has progressed further.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 18 and 55 years old?
Are you a man or a woman?
Are you generally in good health (as a general requirement for Phase I trials)?
Are you able to commit to regular hospital or clinic visits if required?
Are you willing to potentially receive a new, unproven treatment?

Answer every question to see your result.

What does participation involve?

Because the full details of this study are being kept private for now, we don't have exact information about what taking part would involve. Generally, in early-phase studies like this, participants might have several visits to a clinic or hospital for check-ups, tests (like blood tests or scans), and to receive the study treatment. Researchers would closely monitor your health.

You would likely be given a medication or treatment being tested. The number of visits, how long each visit lasts, and the total length of your involvement in the study are currently unknown. There would also be follow-up appointments to see how you are doing after the treatment has finished. Once the full study details are released, this information will become much clearer.

Potential risks and benefits

Since the specific treatment and health condition being studied are not yet public, we can't outline the exact potential benefits or risks. However, in early-stage trials, potential benefits might include early access to a new treatment that could help your condition or contribute to medical science. Risks can include side effects from the new treatment, which can sometimes be unknown, or the need for frequent tests and visits. Remember, you would always have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, England

Common questions

What is a Phase I study?

A Phase I study is usually the first time a new treatment is tested in people. The main goals are to check if it's safe, find the right dose, and see how it works in the body.

Why aren't all the study details available yet?

Sometimes, study sponsors choose to keep full details private for a period, often in early research. All information will be released eventually.

When will the full details of this study be public?

All the details about this study will be made public within 30 months after the study has officially ended.

Who can take part in this study?

The study is looking for both men and women between the ages of 18 and 55 years old. More specific health requirements aren't known yet.

Will I get free treatment if I join?

If you join a clinical trial, the study treatment itself is usually provided at no cost, but you should always discuss this with the research team.

How to find out more

Jennifer Hart

info@evecxia.com +1 (919) 597-8762 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.